Ardelyx (ARDX) Projected to Post Quarterly Earnings on Monday

Key Points

• Ardelyx (NASDAQ: ARDX) is set to release its Q2 2025 earnings results on August 4th, with analysts predicting earnings of ($0.12) per share and revenue of $82.69 million.
• The company reported a 61.1% year-over-year increase in revenue in its last quarterly results, although it missed earnings expectations with $(0.17) EPS.
• Analysts have mixed opinions on the stock, with a consensus rating of "Moderate Buy" and an average target price of $10.89.

Ardelyx (NASDAQ:ARDX - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results after the market closes on Monday, August 4th. Analysts expect Ardelyx to post earnings of ($0.12) per share and revenue of $82.69 million for the quarter.

Ardelyx (NASDAQ:ARDX - Get Free Report) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.07). Ardelyx had a negative net margin of 14.86% and a negative return on equity of 34.45%. The business had revenue of $74.11 million for the quarter, compared to analyst estimates of $79.40 million. During the same quarter in the previous year, the company posted ($0.11) earnings per share. The business's revenue for the quarter was up 61.1% on a year-over-year basis. On average, analysts expect Ardelyx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ardelyx Trading Down 2.4%

Ardelyx stock traded down $0.11 during trading hours on Thursday, reaching $4.24. 1,943,646 shares of the company's stock traded hands, compared to its average volume of 4,729,992. The company has a debt-to-equity ratio of 1.04, a quick ratio of 3.81 and a current ratio of 4.12. Ardelyx has a fifty-two week low of $3.21 and a fifty-two week high of $7.18. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -19.20 and a beta of 0.60. The firm's 50 day moving average is $4.03 and its 200-day moving average is $4.66.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Raymond James Financial downgraded shares of Ardelyx from a "strong-buy" rating to an "outperform" rating and set a $11.00 target price on the stock. in a research report on Friday, May 2nd. HC Wainwright assumed coverage on shares of Ardelyx in a research report on Wednesday, June 18th. They set a "buy" rating and a $10.00 target price on the stock. Wall Street Zen downgraded shares of Ardelyx from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. Finally, Citigroup cut their price target on shares of Ardelyx from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $10.89.

Insider Buying and Selling at Ardelyx

In related news, CFO Justin A. Renz sold 7,218 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $4.08, for a total transaction of $29,449.44. Following the completion of the sale, the chief financial officer directly owned 416,089 shares of the company's stock, valued at approximately $1,697,643.12. This represents a 1.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mike Kelliher sold 14,522 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $4.08, for a total value of $59,249.76. Following the sale, the insider directly owned 282,158 shares of the company's stock, valued at approximately $1,151,204.64. The trade was a 4.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders purchased 881,377 shares of company stock worth $3,402,411 and sold 125,143 shares worth $517,667. 4.80% of the stock is owned by company insiders.

Institutional Trading of Ardelyx

A number of large investors have recently bought and sold shares of the business. Strs Ohio bought a new stake in Ardelyx during the 1st quarter worth approximately $135,000. Focus Partners Wealth bought a new position in shares of Ardelyx during the 1st quarter worth approximately $72,000. Goldman Sachs Group Inc. grew its stake in shares of Ardelyx by 10.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,378,738 shares of the biopharmaceutical company's stock worth $11,680,000 after acquiring an additional 221,486 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Ardelyx by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 159,061 shares of the biopharmaceutical company's stock worth $781,000 after acquiring an additional 4,436 shares in the last quarter. 58.92% of the stock is owned by institutional investors.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.